ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 514

Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?

Matthew McElwee1, Peter Boersma2, Hiba Hashmi3 and Anna K. Shmagel1, 1Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN, 2School of Public Health, University of Minnesota, Minneapolis, MN, 3School of Medicine, University of Minnesota, Minneapolis, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Cholesterol, hypertension, rheumatoid arthritis (RA) and tobacco use

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA) has been well established. While the reasons for an increased risk of CVD in RA remain unclear, it is imperative to carefully manage cardiovascular risk factors in RA patients. The purpose of this study was to compare CVD risk management in seropositive RA patients compared with non-RA patients in a large healthcare system.

Methods:

The study design was a matched retrospective cohort comparing subjects with seropositive RA and non-RA patients drawn from the outpatient population receiving care within the Fairview Health System in Minnesota between 1/1/2005 and 12/31/2015. A cohort of 732 adult subjects with seropositive RA was identified from electronic medical records, and matched with a cohort of 2994 non-RA patients based on age and sex. Demographic characteristics and multiple clinical measures of cardiovascular risk, including BMI, outpatient blood pressure, smoking status, serum lipids and hemoglobin a1c, were ascertained from electronic medical record. Mortality was assessed from medical and state records.Chi-square tests were used for categorical variables and t-tests or Wilcoxon-Mann-Whitney tests for continuous variables. Generalized estimating equation models were used for longitudinal analyses.

Results:

The mean age at baseline was 56 years in both RA and non-RA cohorts, and the majority of patients were female (79% RA, 80% non-RA). Participants in the two cohorts were largely white (82% RA, 85% non-RA), and overweight or obese (baseline BMIs of 25 or greater in 69% RA, and 71% non-RA patients). RA patients, on average, lived in zip codes with a lower median household income than non-RA patients (65,100 vs 67,700, p<0.01). Patients had a minimum of one year follow up (mean 6 years RA, 5.7 years non-RA). There were more deaths in the RA cohort than non-RA cohort during the follow-up period (15% vs 10%, p<0.01). RA patients and non-RA patients, on average, had blood pressure readings, cholesterol and A1C measurements in the normal range, and there was no difference in these parameters between cohorts in longitudinal analyses. Mean systolic blood pressure was 125 and mean diastolic blood pressure was 73 in both RA and no-RA patients. Mean HDL, LDL, Total cholesterol, and A1C were 55±1, 104±2, 188±2, and 6.7±0.1, respectively, for RA patients and 53±0.4, 103±1, 183±1, and 6.9±0.05 for non-RA patients. However, there was a higher percentage of current smokers among RA patients (24% vs. 14%, p<0.01).

Conclusion:

While most CVD risk factors were well managed in seropositive RA patients and in non-RA controls, we found an excess of active smoking in RA patients compared with the non-RA cohort, indicating an area of potential practice improvement.


Disclosure: M. McElwee, None; P. Boersma, None; H. Hashmi, None; A. K. Shmagel, None.

To cite this abstract in AMA style:

McElwee M, Boersma P, Hashmi H, Shmagel AK. Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-risk-management-in-seropositive-rheumatoid-arthritis-what-can-we-do-better/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-management-in-seropositive-rheumatoid-arthritis-what-can-we-do-better/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology